alendronate has been researched along with Osteogenic Sarcoma in 22 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to achieve the purpose of targeting treatment of osteosarcoma, we developed novel paclitaxel (PTX) nanoparticles (Nps) coated with polydopamine (PDA) and grafted by alendronate (ALN) as ligand." | 7.91 | Polydopamine-based surface modification of paclitaxel nanoparticles for osteosarcoma targeted therapy. ( Bi, D; Guo, Y; Han, M; Qi, X; Wang, X; Yue, F; Zhao, L, 2019) |
| "The aim of this paper was to assess the effects of zoledronate (ZOL) and alendronate (FOS) on apoptotic behavior and gene expression of pro- and inflammatory cytokines of three cell types (human osteoblasts, human gingival fibroblasts and human osteogenic sarcoma cell lines) during a period of 4 weeks." | 7.88 | Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells. ( Açil, Y; Arndt, ML; Ayna, M; Gülses, A; Naujokat, H; Wieker, H; Wiltfang, J, 2018) |
| "Two osteosarcoma cell lines (SaOS-2, U(2)OS) were treated with alendronate (50, 100, and 150 microM) for 24 and 48 hr." | 7.72 | Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. ( Cheng, YY; Huang, L; Kumta, SM; Lee, KM; Li, K, 2004) |
| "The bisphosphonate drug alendronate was used to suppress bone remodelling and tumour osteolysis as a palliative treatment for two dogs with osteosarcoma, one of the tibia and one of the maxilla." | 7.70 | Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. ( Muir, P; Pead, MJ; Sturgeon, C; Tomlin, JL, 2000) |
| "Curcumin (CUR) is a general ingredient of traditional Chinese medicine, which has potential antitumor effects." | 5.51 | Dual targeting curcumin loaded alendronate-hyaluronan- octadecanoic acid micelles for improving osteosarcoma therapy. ( Chen, D; He, H; Jiang, T; Shen, Y; Wang, W; Webster, TJ; Wen, J; Xi, Y; Xu, N; Xue, M; Ye, X; Yu, J; Yu, Y, 2019) |
| "3 Pretreatment with alendronate at 100 microM for 24 h prior to the stimulation with tumor necrosis factor-alpha or insulin partially inhibited the IkappaB phosphorylation and degradation." | 5.33 | The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. ( Abe, K; Hirata, M; Inoue, R; Jing, G; Kanematsu, T; Matsuki, NA, 2005) |
| "In order to achieve the purpose of targeting treatment of osteosarcoma, we developed novel paclitaxel (PTX) nanoparticles (Nps) coated with polydopamine (PDA) and grafted by alendronate (ALN) as ligand." | 3.91 | Polydopamine-based surface modification of paclitaxel nanoparticles for osteosarcoma targeted therapy. ( Bi, D; Guo, Y; Han, M; Qi, X; Wang, X; Yue, F; Zhao, L, 2019) |
| "The aim of this paper was to assess the effects of zoledronate (ZOL) and alendronate (FOS) on apoptotic behavior and gene expression of pro- and inflammatory cytokines of three cell types (human osteoblasts, human gingival fibroblasts and human osteogenic sarcoma cell lines) during a period of 4 weeks." | 3.88 | Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells. ( Açil, Y; Arndt, ML; Ayna, M; Gülses, A; Naujokat, H; Wieker, H; Wiltfang, J, 2018) |
| "Alendronate cytotoxicity (10(-3) to 10(-9) mol/L) in human periodontal ligament fibroblasts, human osteogenic sarcoma cells, and murine osteoclastic precursors (RAW 264." | 3.81 | Effects of alendronate on osteoclast formation and activity in vitro. ( Geurtsen, W; Leyhausen, G; Martins, CA; Volk, J, 2015) |
| " This is a follow-up study, its purpose was to examine the effects in-vitro of intravenous zoledronic acid (ZOL) and pamidronate (PAM) and oral alendronate (FOS) on the human oral cavity using gingival fibroblasts and osteoblasts cells and, in addition, osteogenic sarcoma cells (SaOS-2-cells)." | 3.78 | The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells. ( Açil, Y; Gassling, V; Möller, B; Niehoff, P; Rachko, K; Simon, MJ; Wiltfang, J, 2012) |
| " In this study, we investigated the possible direct effect of three N-containing BPs (alendronate, pamidronate, and zoledronate) on the specific activity of bone ALP obtained from an extract of UMR106 rat osteosarcoma cells." | 3.73 | Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations. ( Cortizo, AM; McCarthy, AD; Vaisman, DN, 2005) |
| "Two osteosarcoma cell lines (SaOS-2, U(2)OS) were treated with alendronate (50, 100, and 150 microM) for 24 and 48 hr." | 3.72 | Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. ( Cheng, YY; Huang, L; Kumta, SM; Lee, KM; Li, K, 2004) |
| "The bisphosphonate drug alendronate was used to suppress bone remodelling and tumour osteolysis as a palliative treatment for two dogs with osteosarcoma, one of the tibia and one of the maxilla." | 3.70 | Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. ( Muir, P; Pead, MJ; Sturgeon, C; Tomlin, JL, 2000) |
| "Osteosarcoma is well-known for its high incidence in children and adolescents and long-term bone pain, which seriously reduces the life quality of patients." | 1.91 | Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy. ( Jia, Y; Lan, X; Ma, X; Su, YX; Wang, J; Wang, Y; Wen, W; Zhang, M; Zhong, J, 2023) |
| "Curcumin (CUR) is a general ingredient of traditional Chinese medicine, which has potential antitumor effects." | 1.51 | Dual targeting curcumin loaded alendronate-hyaluronan- octadecanoic acid micelles for improving osteosarcoma therapy. ( Chen, D; He, H; Jiang, T; Shen, Y; Wang, W; Webster, TJ; Wen, J; Xi, Y; Xu, N; Xue, M; Ye, X; Yu, J; Yu, Y, 2019) |
| "Bone neoplasms, such as osteosarcoma, exhibit a propensity for systemic metastases resulting in adverse clinical outcome." | 1.37 | Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances. ( Benayoun, L; Kopeček, J; Kopečková, P; Pan, H; Satchi-Fainaro, R; Segal, E; Shaked, Y, 2011) |
| "3 Pretreatment with alendronate at 100 microM for 24 h prior to the stimulation with tumor necrosis factor-alpha or insulin partially inhibited the IkappaB phosphorylation and degradation." | 1.33 | The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. ( Abe, K; Hirata, M; Inoue, R; Jing, G; Kanematsu, T; Matsuki, NA, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 14 (63.64) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y | 1 |
| Jiang, Z | 1 |
| Tong, S | 1 |
| Sun, Y | 1 |
| Zhang, Y | 1 |
| Zhang, J | 1 |
| Zhao, D | 1 |
| Su, Y | 1 |
| Ding, J | 1 |
| Chen, X | 1 |
| Zhong, J | 3 |
| Wen, W | 3 |
| Wang, J | 3 |
| Zhang, M | 3 |
| Jia, Y | 3 |
| Ma, X | 3 |
| Su, YX | 3 |
| Wang, Y | 3 |
| Lan, X | 3 |
| Xi, Y | 1 |
| Jiang, T | 1 |
| Yu, Y | 1 |
| Yu, J | 1 |
| Xue, M | 1 |
| Xu, N | 1 |
| Wen, J | 1 |
| Wang, W | 1 |
| He, H | 1 |
| Shen, Y | 1 |
| Chen, D | 1 |
| Ye, X | 1 |
| Webster, TJ | 1 |
| Ravanbakhsh, M | 1 |
| Labbaf, S | 1 |
| Karimzadeh, F | 1 |
| Pinna, A | 1 |
| Houreh, AB | 1 |
| Nasr-Esfahani, MH | 1 |
| Wu, H | 1 |
| Luo, Y | 1 |
| Xu, D | 1 |
| Ke, X | 1 |
| Ci, T | 1 |
| Açil, Y | 2 |
| Arndt, ML | 1 |
| Gülses, A | 1 |
| Wieker, H | 1 |
| Naujokat, H | 1 |
| Ayna, M | 1 |
| Wiltfang, J | 2 |
| Feng, S | 1 |
| Wu, ZX | 1 |
| Zhao, Z | 1 |
| Liu, J | 1 |
| Sun, K | 1 |
| Guo, C | 1 |
| Wang, H | 1 |
| Wu, Z | 1 |
| Zhao, L | 1 |
| Bi, D | 1 |
| Qi, X | 1 |
| Guo, Y | 1 |
| Yue, F | 1 |
| Wang, X | 1 |
| Han, M | 1 |
| Morton, SW | 1 |
| Shah, NJ | 1 |
| Quadir, MA | 1 |
| Deng, ZJ | 1 |
| Poon, Z | 1 |
| Hammond, PT | 1 |
| Martins, CA | 1 |
| Leyhausen, G | 1 |
| Volk, J | 1 |
| Geurtsen, W | 1 |
| Liu, P | 1 |
| Sun, L | 1 |
| Zhou, DS | 1 |
| Zhang, P | 1 |
| Wang, YH | 1 |
| Li, D | 1 |
| Li, QH | 1 |
| Feng, RJ | 1 |
| Nguyen, TD | 1 |
| Pitchaimani, A | 1 |
| Aryal, S | 1 |
| Segal, E | 1 |
| Pan, H | 1 |
| Benayoun, L | 1 |
| Kopečková, P | 1 |
| Shaked, Y | 1 |
| Kopeček, J | 1 |
| Satchi-Fainaro, R | 1 |
| Yoshitani, K | 1 |
| Kido, A | 1 |
| Honoki, K | 1 |
| Akahane, M | 1 |
| Fujii, H | 1 |
| Tanaka, Y | 1 |
| Möller, B | 1 |
| Niehoff, P | 1 |
| Rachko, K | 1 |
| Gassling, V | 1 |
| Simon, MJ | 1 |
| Uihlein, AV | 1 |
| Leder, BZ | 1 |
| Carter, CJ | 1 |
| Ward, WG | 1 |
| Cheng, YY | 1 |
| Huang, L | 1 |
| Lee, KM | 1 |
| Li, K | 1 |
| Kumta, SM | 1 |
| Vaisman, DN | 1 |
| McCarthy, AD | 1 |
| Cortizo, AM | 2 |
| Inoue, R | 1 |
| Matsuki, NA | 1 |
| Jing, G | 1 |
| Kanematsu, T | 1 |
| Abe, K | 1 |
| Hirata, M | 1 |
| Molinuevo, MS | 1 |
| Bruzzone, L | 1 |
| Tomlin, JL | 1 |
| Sturgeon, C | 1 |
| Pead, MJ | 1 |
| Muir, P | 1 |
1 review available for alendronate and Osteogenic Sarcoma
| Article | Year |
|---|---|
Anabolic therapies for osteoporosis.
Topics: Alendronate; Anabolic Agents; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agent | 2012 |
21 other studies available for alendronate and Osteogenic Sarcoma
| Article | Year |
|---|---|
Acidity-Triggered Transformable Polypeptide Self-Assembly to Initiate Tumor-Specific Biomineralization.
Topics: Alendronate; Animals; Biomineralization; Bone Neoplasms; Cell Line, Tumor; Glutamic Acid; Mice; Nano | 2023 |
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy.
Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin; | 2023 |
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy.
Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin; | 2023 |
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy.
Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin; | 2023 |
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy.
Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin; | 2023 |
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy.
Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin; | 2023 |
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy.
Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin; | 2023 |
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy.
Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin; | 2023 |
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy.
Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin; | 2023 |
Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy.
Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Child; Cisplatin; | 2023 |
Dual targeting curcumin loaded alendronate-hyaluronan- octadecanoic acid micelles for improving osteosarcoma therapy.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Curcumin; Drug Carrie | 2019 |
Mesoporous bioactive glasses for the combined application of osteosarcoma treatment and bone regeneration.
Topics: Alendronate; Bone Neoplasms; Bone Regeneration; Cell Line; Cell Proliferation; Glass; Humans; Osteob | 2019 |
Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors.
Topics: Alendronate; Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prolif | 2020 |
Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells.
Topics: Alendronate; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokin | 2018 |
Engineering of Bone- and CD44-Dual-Targeting Redox-Sensitive Liposomes for the Treatment of Orthotopic Osteosarcoma.
Topics: Alendronate; Animals; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Female; Humans; Hyaluronan Re | 2019 |
Polydopamine-based surface modification of paclitaxel nanoparticles for osteosarcoma targeted therapy.
Topics: Albumins; Alendronate; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Female; Indo | 2019 |
Osteotropic therapy via targeted layer-by-layer nanoparticles.
Topics: Acrylic Resins; Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, T | 2014 |
Effects of alendronate on osteoclast formation and activity in vitro.
Topics: Alendronate; Animals; Cathepsin K; Cell Proliferation; Cell Survival; Fibroblasts; Humans; Mice; Ost | 2015 |
Development of Alendronate-conjugated Poly (lactic-co-glycolic acid)-Dextran Nanoparticles for Active Targeting of Cisplatin in Osteosarcoma.
Topics: Alendronate; Animals; Bone Neoplasms; Cell Line, Tumor; Cisplatin; Dextrans; Drug Carriers; Humans; | 2015 |
Engineered Nanomedicine with Alendronic Acid Corona Improves Targeting to Osteosarcoma.
Topics: Alendronate; Biocompatible Materials; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Cel | 2016 |
Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances.
Topics: Acrylamides; Alendronate; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Body Weight; Bone | 2011 |
Low concentrations of alendronate increase the local invasive potential of osteoblastic sarcoma cell lines via connexin 43 activation.
Topics: Alendronate; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; C | 2011 |
The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells.
Topics: Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Cell Line, Tumor; Cell Prolifer | 2012 |
Osteosarcoma diagnostic delay associated with alendronate-induced pain relief.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Diagnostic Errors; Humans; Mal | 2012 |
Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines.
Topics: Alendronate; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Dose-Response Relationship, Drug; | 2004 |
Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Resorption; Cations, Divalent; Diph | 2005 |
The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells.
Topics: Alendronate; Cell Death; Cell Line, Tumor; Enzyme Activation; Humans; Insulin; NF-kappa B; Osteosarc | 2005 |
Alendronate induces anti-migratory effects and inhibition of neutral phosphatases in UMR106 osteosarcoma cells.
Topics: Actins; Alendronate; Animals; Bone Density Conservation Agents; Cell Line, Tumor; Cell Movement; Dos | 2007 |
Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs.
Topics: Alendronate; Animals; Bone Neoplasms; Bone Remodeling; Dog Diseases; Dogs; Male; Osteolysis; Osteosa | 2000 |